• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary
    Get the next $ASH alert in real time by email
    SC 13D/A 1 p24-1546sc13da.htm ASHLAND INC.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*
     

    Ashland Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    044186104

    (CUSIP Number)
     
     
    Ricky C. Sandler
    Eminence Capital, LP
    399 Park Avenue, 25th Floor
    New York, New York 10022
    (212) 418-2100
     
    Eleazer Klein, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, New York 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    April 23, 2024

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

    (Page 1 of 7 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 044186104SCHEDULE 13D/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Eminence Capital, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    3,212,068 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    3,212,068 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,212,068 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.4%

    14

    TYPE OF REPORTING PERSON

    IA; PN

             

     

     

    CUSIP No. 044186104SCHEDULE 13D/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Ricky C. Sandler

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    196.66 shares of Common Stock

    8

    SHARED VOTING POWER

    3,212,068 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    196.66 shares of Common Stock

    10

    SHARED DISPOSITIVE POWER

    3,212,068 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,212,264.66 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.4%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 044186104SCHEDULE 13D/APage 4 of 7 Pages

     

    This Amendment No. 4 to the Schedule 13D (this "Amendment No. 4") relates to the common stock, par value $0.01 per share (the "Common Stock"), of Ashland Inc., a Delaware corporation (the "Issuer") and amends the Schedule 13D filed on June 13, 2019 (as amended, the "Schedule 13D"). Capitalized terms used and not defined in this Amendment No. 4 have the meanings set forth in the Original Schedule 13D.  This Amendment No. 4 is being filed to amend Items 3, 4, 5(a)-(c) and 6 of the Schedule 13D as follows:

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
     
    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:
     
      The Reporting Persons used approximately $261,925,094 (including brokerage commissions) in the aggregate to purchase the Common Stock reported in this Schedule 13D.
       
      The source of the funds used to acquire the Common Stock reported herein with respect to the (i) Family Accounts is available funds and (ii) Eminence Funds and SMAs is the working capital of each of the Eminence Funds and SMAs for the shares held by each of them.

     

    Item 4. PURPOSE OF TRANSACTION
     
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
     
      The Reporting Persons sold a portion of their shares of Common Stock for portfolio management reasons.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
    Item 5(a)-(c) of the Schedule 13D are hereby amended and restated in their entirety as follows:
     
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and the percentage of the shares of Common Stock beneficially owned by the Reporting Persons.  The percentages used in this Schedule 13D are calculated based upon 50,094,986 shares of Common Stock outstanding as of December 31, 2023 as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2023 filed by the Issuer with the Securities and Exchange Commission on January 31, 2024.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Information regarding transactions in the shares of Common Stock that have been effected by the Reporting Persons during the past sixty (60) days is set forth in Schedule A which is attached hereto and is incorporated herein by reference.

     

    CUSIP No. 044186104SCHEDULE 13D/APage 5 of 7 Pages

     

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
    Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:
       
     

    The Reporting Persons are parties to an agreement with respect to the joint filing of the Schedule 13D and any amendments thereto. A copy of such agreement is attached as Exhibit 1 to the Schedule 13D and is incorporated by reference herein.

       
      Other than the joint filing agreement, there are no contracts, arrangements, understandings or relationship among the Reporting Persons or between the Reporting Persons and any other person with respect to the securities of the Issuer.

     

     

     

     

    CUSIP No. 044186104SCHEDULE 13D/APage 6 of 7 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: April 25, 2024

     

      /s/ Ricky C. Sandler
      Ricky C. Sandler, individually, and as Chief Executive Officer of Eminence Capital, LP

     

     

    CUSIP No. 044186104SCHEDULE 13D/APage 7 of 7 Pages

     

    Schedule A

    TRANSACTIONS IN THE ISSUER'S SHARES OF COMMON STOCK BY THE REPORTING PERSONS DURING THE PAST SIXTY (60) DAYS

     

    The following table sets forth all transactions with respect to the shares of Common Stock effected during the past sixty (60) days by the Reporting Persons, which were all effected in the open market through a broker.

    Trade Date Amount Purchased (Sold) Price Per Share ($)
    02/26/2024 (52,386) 93.40
    02/27/2024 (53,284) 93.64
    03/01/2024 (10,585) 93.64
    03/01/2024 3,947 93.65
    03/15/2024 23,019 96.73
    03/19/2024 (10,709) 95.77
    03/21/2024 (97,771) 95.98
    04/01/2024 50,331 97.34
    04/01/2024 (30,354) 97.36
    04/04/2024 11,491 96.31
    04/12/2024 (12,998) 95.05
    04/15/2024 (36,498) 93.94
    04/18/2024 (7,387) 95.16
    04/19/2024 (6,465) 95.67
    04/23/2024 (41,416) 96.45

     

    Get the next $ASH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ASH

    DatePrice TargetRatingAnalyst
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    3/5/2025Buy → Neutral
    Seaport Research Partners
    8/8/2024$90.00 → $89.00Underweight → Neutral
    JP Morgan
    4/11/2024$100.00 → $112.00Equal Weight → Overweight
    Wells Fargo
    3/14/2024$100.00 → $126.00Hold → Buy
    Jefferies
    3/1/2024$108.00Outperform
    Wolfe Research
    6/29/2023Outperform → In-line
    Evercore ISI
    More analyst ratings

    $ASH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and GM, Life Sciences Assis Alessandra Faccin exercised 3,123 shares at a strike of $51.26 and covered exercise/tax liability with 1,327 shares, increasing direct ownership by 57% to 4,946 units (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      7/28/25 4:30:42 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by SVP, CFO & PFO Whitaker William

      4 - ASHLAND INC. (0001674862) (Issuer)

      7/22/25 4:30:07 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Chattopadhyay Sanat

      4 - ASHLAND INC. (0001674862) (Issuer)

      7/2/25 4:30:04 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    SEC Filings

    See more
    • Amendment: Ashland Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - ASHLAND INC. (0001674862) (Filer)

      7/28/25 5:29:28 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland Inc. filed SEC Form 8-K: Leadership Update

      8-K - ASHLAND INC. (0001674862) (Filer)

      7/21/25 5:02:09 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ASHLAND INC. (0001674862) (Filer)

      7/14/25 5:02:47 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      2/3/25 4:30:05 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SVP and GM, Life Sciences Assis Alessandra Faccin bought $201,600 worth of shares (3,150 units at $64.00) (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      2/3/25 4:30:03 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ashland downgraded by Wells Fargo

      Wells Fargo downgraded Ashland from Overweight to Equal Weight

      5/1/25 3:02:01 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland upgraded by Analyst with a new price target

      Analyst upgraded Ashland from Neutral to Overweight and set a new price target of $71.00 from $68.00 previously

      3/26/25 7:45:24 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland downgraded by Seaport Research Partners

      Seaport Research Partners downgraded Ashland from Buy to Neutral

      3/5/25 7:22:09 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ashland Inc.

      SC 13G - ASHLAND INC. (0001674862) (Subject)

      11/12/24 11:54:03 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Ashland Inc.

      SC 13G/A - ASHLAND INC. (0001674862) (Subject)

      7/10/24 1:14:41 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

      SC 13D/A - ASHLAND INC. (0001674862) (Subject)

      4/25/24 4:15:12 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Whitaker named senior vice president and chief financial officer, Ashland

      WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that the board of directors has named William C. Whitaker, senior vice president and chief financial officer, Ashland, effective July 18, 2025. Whitaker has been serving as the company's interim chief financial officer. Whitaker joined Ashland in 2015. He has held several positions of increasing responsibility in corporate development, treasury, financial planning and analysis (FP&A) and investor relations. Prior to Ashland, Whitaker held roles outside of the company within private equity and transaction advisory services. He earned a Bachelor's degree in Finance from Ohio State University and h

      7/21/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland sets date for third-quarter fiscal 2025 earnings release and conference call webcast

      WILMINGTON, Del., July 16, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its third-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, July 29, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Wednesday, July 30. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, interim chief financial officerDago C

      7/16/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Operations leadership changes announced at Ashland

      WILMINGTON, Del., July 14, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Karl Bostaph, senior vice president, operations will retire on October 1, 2025. Bostaph joined Hercules in 1990 which was acquired by Ashland in 2008.  Over the course of his career at Ashland, Bostaph held roles in Research and Development, Quality, Engineering and Process Technology, and Manufacturing at multiple U.S. locations. He also spent a portion of his career at manufacturing facilities outside of the United States (US) in several regional and global leadership positions. Last year, Bostaph led operations as the company finalized its portfolio optimization initiatives, and most rec

      7/14/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Leadership Updates

    Live Leadership Updates

    See more
    • Ashland announces executive leadership changes

      WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

      5/5/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

      Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

      9/3/24 7:00:00 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

      Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio

      9/3/24 7:00:00 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Financials

    Live finance-specific insights

    See more
    • Ashland sets date for third-quarter fiscal 2025 earnings release and conference call webcast

      WILMINGTON, Del., July 16, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its third-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, July 29, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Wednesday, July 30. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, interim chief financial officerDago C

      7/16/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland board authorizes quarterly dividend

      WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock which represents a 2.5 percent increase from the previous quarter. The dividend will be payable on June 15, 2025, to stockholders of record at the close of business on June 1, 2025. As of April 30, 2025, there were 45,696,225 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of

      5/6/25 5:15:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland reports second quarter fiscal 2025 results and revises full-year outlook

      Sales of $479 million, down 17 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), nutraceuticals and Avoca portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $67 million or 12 percent versus the prior-year quarter. Excluding these initiatives, sales declined five percent.Income from continuing operations of $30 million, or $0.63 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $46 million, or $0.99 per diluted shareNet income of $31 million, or $0.65 per diluted shareAdjusted EBITDA of $108 million, down 14 percent f

      4/30/25 5:01:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary